Table 4.
All-grade AEs occurring in ≥ 10% of all patients during NFF.
| All grades, n (%) | Grade ≥ 3, n (%) | |
|---|---|---|
| Hematologic | ||
| Neutropenia | 68 (42) | 38 (23) |
| Leukopenia | 66 (41) | 19 (12) |
| Anemia | 86 (53) | 15 (9) |
| Thrombocytopenia | 20 (12) | 2 (1) |
| Nonhematologic | ||
| Anorexia | 118 (73) | 20 (12) |
| Malaise | 94 (58) | 5 (3) |
| Fatigue | 79 (49) | 5 (3) |
| Nausea | 68 (42) | 9 (6) |
| Vomiting | 32 (20) | 2 (1) |
| Diarrhea | 51 (32) | 5 (3) |
| Constipation | 50 (31) | 0 (0) |
| Liver enzyme elevation | 41 (25) | 2 (1) |
| Peripheral sensory neuropathy | 63 (39) | 1 (1) |
| Oral mucositis | 20 (12) | 1 (1) |
| Alopecia | 36 (22) | 0 (0) |
Abbreviations: AE Adverse Event, NFF Nanoliposomal irinotecan and fluorouracil with folinic acid.